A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET — SORENTO

Gastro-enteropancreatic Neuroendocrine Tumor Clinical Trial

Official title:
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Gastro-enteropancreatic Neuroendocrine Tumor
Neuroendocrine Tumors

Clinical Trial Details

NCT number	NCT05050942
Study type	Interventional
Source	Camurus AB
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	October 22, 2021
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04614766` - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors	Phase 1/Phase 2
Completed	`NCT03220217` - To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)	Phase 2
Recruiting	`NCT03475953` - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06253897` - A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Recruiting	`NCT03863106` - The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
Active, not recruiting	`NCT03972488` - Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET	Phase 3
Terminated	`NCT03042780` - FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas	Phase 2
Active, not recruiting	`NCT03600233` - Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors	Phase 2
Completed	`NCT01423734` - The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Withdrawn	`NCT02779257` - Pasireotide Treatment for Neuroendocrine Tumor	Phase 4